Electronic Quitline Referral With Enhanced Academic Detailing for the Promotion of Smoking Cessation
Launched by OHSU KNIGHT CANCER INSTITUTE · Jul 9, 2021
Trial Information
Current as of September 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
PRIMARY OBJECTIVES:
I. Implement a Quitline electronic (e)Referral system with enhanced academic detailing (AD) (intervention; n=10 community health centers \[CHCs\]) and without enhanced AD (comparison; n=10 CHCs) to compare rates of eReferral offers, eReferral acceptance, Quitline enrollment, orders for tobacco cessation medication, and receipt of in-clinic counseling among patients identified as currently using tobacco.
II. Assess the effectiveness of implementing a Quitline eReferral system with enhanced AD (intervention) versus without enhanced AD (comparison) on self-reported tobacc...
Gender
ALL
Eligibility criteria
- Study Clinic Inclusion Criteria:
- • In Oregon
- • On the OCHIN Epic EHR for \>= 1 year
- • Willing to be randomized to the intervention or comparison condition
- • Willing to recruit a provider to serve as a clinic champion (to share monthly performance audit and feedback at all-staff meetings, determine desired content of booster sessions with clinic team members, and complete a survey at the completion of the intervention period) and a clinic manager to coordinate training and booster sessions
- Study Patient Inclusion Criteria:
- • Adult patients (\>= 18 years of age)
- • Identified as current tobacco users during \>= 1 ambulatory and/or telehealth visit to one of the eligible study clinics over the 24-month study period
About Ohsu Knight Cancer Institute
The OHSU Knight Cancer Institute is a leading research and treatment center dedicated to advancing cancer care through innovative clinical trials and groundbreaking research. Part of Oregon Health & Science University, the institute is recognized for its multidisciplinary approach, combining expertise in oncology, genomics, and patient care to develop novel therapies and improve treatment outcomes. With a commitment to translating scientific discoveries into clinical applications, the OHSU Knight Cancer Institute strives to enhance the quality of life for cancer patients while fostering collaboration among researchers, clinicians, and the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Patients applied
Trial Officials
Steffani Bailey
Principal Investigator
OHSU Department of Family Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials